Effect of L Carnitine on severity of uremic restless legs syndrome
Phase 2
Recruiting
- Conditions
- Restless leg syndrome.Restless legs syndromeG25.81
- Registration Number
- IRCT20130812014333N171
- Lead Sponsor
- Kermanshah University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 82
Inclusion Criteria
Dialysis patients with restless legs syndrome
Patient informed consent
Exclusion Criteria
Patients diagnosed with anxiety disorders
Patients with a diagnosis of sleep disorders
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of Restless Legs Syndrome. Timepoint: Beginning of treatment, sixth week and end of treatment (three months later). Method of measurement: Based on clinical observation, physician and patient opinion.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie L-Carnitine's efficacy in uremic restless legs syndrome (G25.81) among dialysis patients?
How does L-Carnitine compare to standard-of-care treatments for uremic RLS (G25.81) in IRCT20130812014333N171 phase II trials?
What biomarkers predict L-Carnitine response in IRCT20130812014333N171 uremic RLS (G25.81) patients, including plasma carnitine or dopamine receptor polymorphisms?
What adverse events are associated with L-Carnitine therapy in IRCT20130812014333N171 dialysis patients with uremic RLS (G25.81), and how are they managed?
What combination therapies or competitor drugs are evaluated with L-Carnitine for uremic RLS (G25.81) in Kermanshah University's phase II trials?